Risk factors of positive surgical margins after robot-assisted radical prostatectomy in high-volume center: results in 732 cases.

Positive surgical margins Prostate cancer Prostate cancer tumor-grade groups Radical prostatectomy Robotic surgery

Journal

Journal of robotic surgery
ISSN: 1863-2491
Titre abrégé: J Robot Surg
Pays: England
ID NLM: 101300401

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 03 01 2019
accepted: 28 03 2019
pubmed: 7 4 2019
medline: 20 8 2020
entrez: 7 4 2019
Statut: ppublish

Résumé

The aim of the study was to evaluate clinical, pathological and peri-operative factors associated with the risk of positive surgical margins (PSM) after robot-assisted radical prostatectomy (RARP) in a high-volume center. The study is a retrospective analysis of prospectively collected data. We excluded cases who were under androgen deprivation or had prior treatments. The population included negative cases (control group) and PSM subjects (study groups). The logistic regression model assessed the independent association of factors with the risk of PSM. From January 2013 to December 2017, 732 patients underwent RARP. Extended pelvic lymph node dissection was performed in 342 cases (46.7%). Overall, 192 cases (26.3%) had PSM. Independent factors associated with the risk of focal PSM were body mass index (odds ratio, OR = 0.936; p = 0.021), percentage of biopsy-positive cores (BPC; OR = 1.012; p = 0.004), pathological extracapsular extension (OR = 2.702; p < 0.0001), seminal vesicle invasion (OR = 2.889; p < 0.0001) and high-volume surgeon (OR = 0.607; p = 0.006). In high-volume centers, features related to host, tumor biology and surgeon are independent factors associated with the risk of PSM after RARP, which are decreased by the high-volume surgeon. The inverse association between BMI and PSM risk needs further clinical research. These issues should be discussed when counseling patients.

Identifiants

pubmed: 30953271
doi: 10.1007/s11701-019-00954-x
pii: 10.1007/s11701-019-00954-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-175

Références

Eur Urol. 2014 Feb;65(2):303-13
pubmed: 23932439
Minerva Urol Nefrol. 2017 Feb;69(1):63-68
pubmed: 28009146
World J Urol. 2008 Feb;26(1):91-5
pubmed: 17940773
Eur Urol Focus. 2018 Apr;4(3):351-359
pubmed: 28753802
Eur Urol. 2012 Sep;62(3):368-81
pubmed: 22763081
Curr Urol. 2017 Aug;10(3):118-125
pubmed: 28878593
BJU Int. 2013 Jun;111(8):E290-9
pubmed: 23489974
Eur Urol Focus. 2018 Dec;4(6):775-789
pubmed: 28753874
J Robot Surg. 2019 Feb;13(1):83-89
pubmed: 29737495
J Clin Oncol. 2008 May 10;26(14):2278-84
pubmed: 18467718
J Urol. 2003 Jun;169(6):2289-92
pubmed: 12771773
Eur Urol. 2009 Jan;55(1):87-99
pubmed: 18838211
Minerva Urol Nefrol. 2017 Oct;69(5):493-500
pubmed: 28376606
Arch Pathol Lab Med. 2009 Oct;133(10):1568-76
pubmed: 19792046
JAMA. 1961 Oct 21;178:261-6
pubmed: 13887881
J Surg Oncol. 2016 Mar;113(3):310-5
pubmed: 27004601
Eur Urol. 2006 May;49(5):866-71; discussion 871-2
pubmed: 16564614
J Urol. 2011 Aug;186(2):511-6
pubmed: 21680001
Urol Int. 2018;100(3):251-262
pubmed: 29161715
Urology. 2009 Feb;73(2):316-22
pubmed: 18952266
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Can Urol Assoc J. 2014 May;8(5-6):195-201
pubmed: 25024790
Can J Urol. 2010 Aug;17(4):5291-8
pubmed: 20735909
Urol Oncol. 2010 Mar-Apr;28(2):197-204
pubmed: 20219559
Urol Oncol. 2013 Oct;31(7):974-9
pubmed: 22244265
Urol Int. 2018;101(1):38-46
pubmed: 29975957
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Urol Oncol. 2010 Mar-Apr;28(2):210-4
pubmed: 20219561
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Scand J Urol. 2013 Apr;47(2):92-100
pubmed: 22860630
Eur Urol. 2009 Dec;56(6):972-80
pubmed: 19781848
J Robot Surg. 2016 Sep;10(3):187-200
pubmed: 27251473
Eur Urol. 2010 Jun;57(6):1022-9
pubmed: 20163911
World J Urol. 2010 Dec;28(6):699-704
pubmed: 20033185
Urol Int. 2017;99(2):207-214
pubmed: 28245480
J Urol. 2009 Dec;182(6):2682-8
pubmed: 19836778

Auteurs

Antonio Benito Porcaro (AB)

Department of Urology, University of Verona, Verona, Italy. drporcaro@yahoo.com.

Marco Sebben (M)

Department of Urology, University of Verona, Verona, Italy.

Paolo Corsi (P)

Department of Urology, University of Verona, Verona, Italy.

Alessandro Tafuri (A)

Department of Urology, University of Verona, Verona, Italy.

Tania Processali (T)

Department of Urology, University of Verona, Verona, Italy.

Marco Pirozzi (M)

Department of Urology, University of Verona, Verona, Italy.

Nelia Amigoni (N)

Department of Urology, University of Verona, Verona, Italy.

Riccardo Rizzetto (R)

Department of Urology, University of Verona, Verona, Italy.

Giovanni Cacciamani (G)

Department of Urology, University of Verona, Verona, Italy.

Arianna Mariotto (A)

Department of Urology, University of Verona, Verona, Italy.

Alberto Diminutto (A)

Department of Urology, University of Verona, Verona, Italy.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Verona, Italy.

Vincenzo De Marco (V)

Department of Urology, University of Verona, Verona, Italy.

Salvatore Siracusano (S)

Department of Urology, University of Verona, Verona, Italy.

Walter Artibani (W)

Department of Urology, University of Verona, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH